Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David N Church

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
Cancer Immunology Research|August 29, 2025
Spatiotemporal immune landscape and long-term immune memory in POLE-mutant endometrial cancer at the single-cell levelKoen Brummel, Marta Requesens, Nienke van Rooij, et al.
The Journal of Pathology|December 13, 2019
Interpretation of somatic POLE mutations in endometrial carcinomaAlicia León-Castillo, Heidi Britton, Melissa K McConechy, et al.
Clinical Genitourinary Cancer|January 17, 2018
Changing Practice Evaluation-Stage 1 Seminoma: Outcomes With Adjuvant Treatment Versus Surveillance: Risk Factors for Recurrence and Optimizing Follow-up Protocols-Experience From a Supraregional CenterHelen E J Tyrrell, David N Church, Johnson Joseph, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2018
Adjuvant Treatment for <i>POLE</i> Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside AnaloguesInge C Van Gool, Emily Rayner, Elisabeth M Osse, et al.
Human Molecular Genetics|March 27, 2013
DNA polymerase ε and δ exonuclease domain mutations in endometrial cancerDavid N Church, Sarah E W Briggs, Claire Palles, et al.
ESMO Open|February 22, 2020
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised studyDavid Lau, Eleftheria Kalaitzaki, David N Church, et al.
Genome Medicine|August 25, 2025
Replication-associated mechanisms contribute to an increased CpG > TpG mutation burden in mismatch repair-deficient cancersJoseph C Ward, Ignacio Soriano, Steve Thorn, et al.
British Journal of Cancer|August 8, 2019
Tumour-infiltrating CD8<sup>+</sup> lymphocytes and colorectal cancer recurrence by tumour and nodal stageMark A Glaire, Enric Domingo, Anita Sveen, et al.
Nature Genetics|February 13, 2026
Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer typesAndrew Everall, Avraam Tapinos, Aliah Hawari, et al.
British Journal of Cancer|September 25, 2019
Correction: Tumour-infiltrating CD8<sup>+</sup> lymphocytes and colorectal cancer recurrence by tumour and nodal stageMark A Glaire, Enric Domingo, Anita Sveen, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Cancer Immunology Research|August 29, 2025
Spatiotemporal immune landscape and long-term immune memory in POLE-mutant endometrial cancer at the single-cell levelKoen Brummel, Marta Requesens, Nienke van Rooij, et al.
The Journal of Pathology|December 13, 2019
Interpretation of somatic POLE mutations in endometrial carcinomaAlicia León-Castillo, Heidi Britton, Melissa K McConechy, et al.
Clinical Genitourinary Cancer|January 17, 2018
Changing Practice Evaluation-Stage 1 Seminoma: Outcomes With Adjuvant Treatment Versus Surveillance: Risk Factors for Recurrence and Optimizing Follow-up Protocols-Experience From a Supraregional CenterHelen E J Tyrrell, David N Church, Johnson Joseph, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2018
Adjuvant Treatment for <i>POLE</i> Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside AnaloguesInge C Van Gool, Emily Rayner, Elisabeth M Osse, et al.
Human Molecular Genetics|March 27, 2013
DNA polymerase ε and δ exonuclease domain mutations in endometrial cancerDavid N Church, Sarah E W Briggs, Claire Palles, et al.
ESMO Open|February 22, 2020
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised studyDavid Lau, Eleftheria Kalaitzaki, David N Church, et al.
Genome Medicine|August 25, 2025
Replication-associated mechanisms contribute to an increased CpG > TpG mutation burden in mismatch repair-deficient cancersJoseph C Ward, Ignacio Soriano, Steve Thorn, et al.
British Journal of Cancer|August 8, 2019
Tumour-infiltrating CD8<sup>+</sup> lymphocytes and colorectal cancer recurrence by tumour and nodal stageMark A Glaire, Enric Domingo, Anita Sveen, et al.
Nature Genetics|February 13, 2026
Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer typesAndrew Everall, Avraam Tapinos, Aliah Hawari, et al.
British Journal of Cancer|September 25, 2019
Correction: Tumour-infiltrating CD8<sup>+</sup> lymphocytes and colorectal cancer recurrence by tumour and nodal stageMark A Glaire, Enric Domingo, Anita Sveen, et al.
Pageof 7